-
EP3773637
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3773637
| EP3773637 - METHODS FOR TREATING SICKLE CELL DISEASE [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 15.01.2021 Database last updated on 09.09.2024 | |
| Former | The international publication has been made Status updated on 19.10.2019 | Most recent event Tooltip | 29.04.2024 | New entry: Renewal fee paid | Applicant(s) | For all designated states The Regents of the University of California 1111 Franklin Street, 12th Floor Oakland, CA 94607 / US | For all designated states Kohn, Donald, B. 200 UCLA Medical Plaza Suite 265 Los Angeles CA 90095 / US | For all designated states Romero Garcia, Zulema 1602 Molecular Sciences Building 609 Charles E. Young Drive, East Los Angeles CA 90095 / US | [2021/07] | Inventor(s) | 01 /
DEWITT, Mark, A. 2151 Berkeley Way Energy Biosciences Building, RM 220 Berkeley, California 94704 / US | 02 /
MARTIN, David, I. 5700 Martin Luther King Jr. Way Oakland, California 94609 / US | 03 /
MAGIS, Wendy 5700 Martin Luther King Jr. Way Oakland, California 94609 / US | 04 /
CORN, Jacob, E. 2151 Berkeley Way Energy Biosciences Building, RM 220 Berkeley, California 94704 / US | 05 /
WALTERS, Mark, C. 231 La Serena Ave Alamo, California 94507 / US | 06 /
KOHN, Donald, B. 200 UCLA Medical Plaza, Suite 265 Los Angeles, California 90095 / US | 07 /
ROMERO GARCIA, Zulema 1602 Molecular Sciences Building 609 Charles E. Young Drive, East Los Angeles, California 90095 / US | [2021/07] | Representative(s) | Mewburn Ellis LLP Aurora Building Counterslip Bristol BS1 6BX / GB | [N/P] |
| Former [2021/07] | Mewburn Ellis LLP Aurora Building Counterslip Bristol BS1 6BX / GB | Application number, filing date | 19785436.7 | 10.04.2019 | [2021/07] | WO2019US26806 | Priority number, date | US201862657412P | 13.04.2018 Original published format: US 201862657412 P | [2021/07] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2019199984 | Date: | 17.10.2019 | Language: | EN | [2019/42] | Type: | A1 Application with search report | No.: | EP3773637 | Date: | 17.02.2021 | Language: | EN | The application published by WIPO in one of the EPO official languages on 17.10.2019 takes the place of the publication of the European patent application. | [2021/07] | Search report(s) | International search report - published on: | US | 17.10.2019 | (Supplementary) European search report - dispatched on: | EP | 15.11.2021 | Classification | IPC: | A61K35/28, C12N5/0789, C12N9/22, C12N15/09, C12N15/11, C12N15/90 | [2021/07] | CPC: |
A61K35/28 (EP);
C12N15/113 (EP,US);
A61P7/00 (EP);
C07K14/805 (EP);
C12N15/102 (US);
C12N5/0647 (US);
C12N9/22 (EP,US);
C12N2310/20 (EP,US);
C12N2310/315 (EP);
C12N2310/3181 (US);
C12N2310/344 (EP);
C12N2310/346 (US);
C12N2510/00 (US)
(-)
| C-Set: |
C12N2310/321, C12N2310/3521 (EP)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2021/07] | Title | German: | VERFAHREN ZUR BEHANDLUNG DER SICHELZELLKRANKHEIT | [2021/07] | English: | METHODS FOR TREATING SICKLE CELL DISEASE | [2021/07] | French: | MÉTHODES DE TRAITEMENT DE LA DRÉPANOCYTOSE | [2021/07] | Entry into regional phase | 27.10.2020 | National basic fee paid | 27.10.2020 | Search fee paid | 27.10.2020 | Designation fee(s) paid | 27.10.2020 | Examination fee paid | Examination procedure | 27.10.2020 | Examination requested [2021/07] | 07.06.2022 | Amendment by applicant (claims and/or description) | Fees paid | Renewal fee | 27.04.2021 | Renewal fee patent year 03 | 27.04.2022 | Renewal fee patent year 04 | 27.04.2023 | Renewal fee patent year 05 | 29.04.2024 | Renewal fee patent year 06 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [Y]WO2016154596 (EDITAS MEDICINE INC [US]) [Y] 1-15 * example 11 *; | [Y]WO2017053729 (UNIV LELAND STANFORD JUNIOR [US]) [Y] 1-15 * paragraphs [0057] , [0 59] , [ 255] *; | [XYI] - DANIEL P. DEVER ET AL, "The changing landscape of gene editing in hematopoietic stem cells : a step towards Cas9 clinical translation", CURRENT OPINION IN HEMATOLOGY, US, (20171101), vol. 24, no. 6, doi:10.1097/MOH.0000000000000385, ISSN 1065-6251, pages 481 - 488, XP055669388 [X] 1,2,6,10-13 * The whole document, and in particular Figure 1 and Table 1 * [Y] 7-9,14 [I] 3-5,15 DOI: http://dx.doi.org/10.1097/MOH.0000000000000385 | [Y] - DEVER DANIEL P ET AL, "CRISPR/Cas9 [beta]-globin gene targeting in human haematopoietic stem cells", NATURE, NATURE PUBLISHING GROUP UK, LONDON, vol. 539, no. 7629, doi:10.1038/NATURE20134, ISSN 0028-0836, (20161107), pages 384 - 389, (20161107), XP037555923 [Y] 1-15 * the whole document * DOI: http://dx.doi.org/10.1038/nature20134 | [A] - MATTHEW C CANVER AND STUART H ORKIN, "Customizing the genome as therapy for the [beta]-hemoglobinopathies", vol. 127, no. 21, doi:10.1182/BLOOD-2016-01-678128, (20160406), pages 2536 - 2545, BLOOD,, URL: http://www.bloodjournal.org/content/127/21/2536?sso-checked=true, XP002771817 [A] 1-15 * the whole document * DOI: http://dx.doi.org/10.1182/blood-2016-01-678128 | [T] - ROMERO ZULEMA ET AL, "Editing the Sickle Cell Disease Mutation in Human Hematopoietic Stem Cells: Comparison of Endonucleases and Homologous Donor Templates", MOLECULAR THERAPY, US, (20190801), vol. 27, no. 8, doi:10.1016/j.ymthe.2019.05.014, ISSN 1525-0016, pages 1389 - 1406, XP055857667 [T] 1-15 * the whole document * DOI: http://dx.doi.org/10.1016/j.ymthe.2019.05.014 | International search | [Y]US2016120947 (SCADDEN DAVID T [US], et al) [Y] 1-12, 14-53, 55, 56 * entire document *; | [Y]US2016281111 (COTTA-RAMUSINO CECILIA [US], et al) [Y] 15, 56 * entire document *; | [Y]WO2017123609 (UNIV CALIFORNIA [US]) [Y] 1-12, 14-20, 42-53, 55, 56 * entire document *; | [Y] - DEWITT et al., "Selection-free genome editing of the sickle mutation in human adult hematopoietic stem/progenitor cells", Science Translational Medicine, (20161012), vol. 8, no. 360, pages 1 - 9, XP055312749 [Y] 1, 21-41 * . entire document * DOI: http://dx.doi.org/10.1126/scitranslmed.aaf9336 | [Y] - RYAN et al., "Improving CRISPR-Cas specificity with chemical modifications in single-guide RNAs", Nucleic Acids Res, (20180125), vol. 46, no. 2, pages 792 - 803, XP055643341 [Y] 9-11, 31-33, 51-53 * . entire document . * DOI: http://dx.doi.org/10.1093/nar/gkx1199 | [A] - ABUDAYYEH et al., "RNA targeting with CRISPR-Cas13", Nature, (20171012), vol. 550, no. 7675, doi:10.1038/nature24049, pages 280 - 284, XP055529736 [A] 1-56 * . entire document * DOI: http://dx.doi.org/10.1038/nature24049 | [A] - HOBAN et al., "CRISPR/Cas9-Mediated Correction of the Sickle Mutation in Human CD 34+ cells", MOLECULAR THERAPY, (20160729), vol. 24, no. 9, doi:10.1038/mt.2016.148, pages 1561 - 1569, XP055419337 [A] 1-56 * . entire document * DOI: http://dx.doi.org/10.1038/mt.2016.148 | [A] - KLEINSTIVER et al., "High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects", Nature, (20160106), vol. 529, doi:10.1038/nature16526, pages 490 - 495, XP055555618 [A] 1-56 * . entire document * DOI: http://dx.doi.org/10.1038/nature16526 |